CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2, 36-Week, Open-Label, Uncontrolled Safety Follow-up Study Assessing SCH 420814 (Preladenant) 5 mg BID (P05175)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00537017
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:50.243221+00:00
Published At: 2016-12-06T00:00:00+00:00
Record Updated At: 2021-02-02
Results Posted At: 2016-12-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Parkinson Disease", "Neurodegenerative Diseases", "Central Nervous System Diseases", "Movement Disorders", "Brain Diseases"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-02-02"
protocolSection.identificationModule.nctId: "NCT00537017"
protocolSection.identificationModule.officialTitle: "A Phase 2, 36-Week, Open-Label, Uncontrolled Safety Follow-up Study Assessing SCH 420814 (Preladenant) 5 mg BID (P05175)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2016-12-06"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.